Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bluebird Bio (BLUE)

Bluebird Bio (BLUE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Sage Therapeutic is Among the Companies in the Biotechnology Industry with the Best Relative Performance (SAGE , PBYI , BLUE , ATRA , REGN )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

BLUE : 89.75 (+6.78%)
PBYI : 9.36 (+0.75%)
SAGE : 72.87 (+0.39%)
Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar

The biotech sector witnesses pipeline updates from the annual ASH meet.

GILD : 65.77 (-2.75%)
AMGN : 236.74 (+0.32%)
BLUE : 89.75 (+6.78%)
FATE : 18.79 (-0.69%)
VRTX : 218.98 (-0.71%)
REGN : 376.42 (+1.14%)
SAGE : 72.87 (+0.39%)
Fate (FATE) Announces Encouraging Data on Immunotherapies

Fate (FATE) gains on positive data from cellular immunotherapies and preclinical study data.

BMY : 63.82 (-0.19%)
GILD : 65.77 (-2.75%)
FATE : 18.79 (-0.69%)
BLUE : 89.75 (+6.78%)
bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition

--CAR T persistence observed in 8/10 evaluable responders at Month 6 and 2/2 evaluable responders at Month 18

BLUE : 89.75 (+6.78%)
BMY : 63.82 (-0.19%)
bluebird bio Presents New Data Demonstrating Long-Term Transfusion Independence and Safety for LentiGlobin(TM) Gene Therapy for B-thalassemia (betibeglogene autotemcel) at 61st ASH Annual Meeting and Exposition

--Ninety percent of evaluable patients who do not have a B(0)/B(0 )genotype achieved TI, with median average total Hb levels of 12.2 g/dL in Phase 3 Northstar-2 (HGB-207) study

BLUE : 89.75 (+6.78%)
bluebird Reports Positive Top-Line Data on Myeloma Drug

bluebird (BLUE) and partner Bristol-Myers report positive top-line results from a phase II study on idecabtagene vicleucel in patients with relapsed and refractory multiple myeloma.

BMY : 63.82 (-0.19%)
BLUE : 89.75 (+6.78%)
ANIK : 53.15 (-0.65%)
ALKS : 20.87 (-1.79%)
Look for Shares of Bluebird Bio Inc to Potentially Rebound after Yesterday's 2.69% Sell Off

Bluebird Bio Inc (NASDAQ:BLUE) traded in a range yesterday that spanned from a low of $75.11 to a high of $83.92. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of...

BLUE : 89.75 (+6.78%)
bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin(TM) Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition

--Group C patients at six months post-treatment produced consistent median levels of gene therapy-derived anti-sickling hemoglobin (HbAT87Q) ranging from 44 - 59% (Month 6 - 21), reducing the median level...

BLUE : 89.75 (+6.78%)
Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma

--Safety results are consistent with the data presented in CRB-401 study

BMY : 63.82 (-0.19%)
BLUE : 89.75 (+6.78%)
Stocks Rebound and Hang Onto Recent Gains

Stocks Rebound and Hang Onto Recent Gains

ORI : 22.43 (-1.10%)
AOBC : 9.24 (-0.27%)
RLGY : 10.82 (+1.22%)
BLUE : 89.75 (+6.78%)
TRHC : 38.20 (-0.03%)
NVTA : 17.16 (+0.76%)
Look for Shares of Bluebird Bio Inc to Potentially Pullback after Yesterday's 1.83% Rise

Bluebird Bio Inc (NASDAQ:BLUE) traded in a range yesterday that spanned from a low of $80.20 to a high of $85.33. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high...

BLUE : 89.75 (+6.78%)
Are Options Traders Betting on a Big Move in bluebird (BLUE) Stock?

Investors need to pay close attention to bluebird (BLUE) stock based on the movements in the options market lately.

BLUE : 89.75 (+6.78%)
bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 9, 2019 at 8:00 p.m. ET to review clinical data presented at the 61st American Society of Hematology...

BLUE : 89.75 (+6.78%)
Global Blood's (GBT) Oxbryta Secures FDA Approval for SCD

Global Blood's (GBT) Oxbryta wins the FDA nod to address sickle cell disease in patients aged 12 years and above. The approval comes three months ahead of schedule.

NVS : 92.99 (-0.08%)
BLUE : 89.75 (+6.78%)
GBT : 76.88 (-0.01%)
ANIK : 53.15 (-0.65%)
Bluebird Bio Inc Set to Possibly Pullback After Yesterday's Rally of 3.57%

Bluebird Bio Inc (NASDAQ:BLUE) traded in a range yesterday that spanned from a low of $76.72 to a high of $78.80. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high...

BLUE : 89.75 (+6.78%)
Bluebird Bio Inc Shares Down 40.6% Since SmarTrend's Sell Call (BLUE)

SmarTrend identified a Downtrend for Bluebird Bio Inc (NASDAQ:BLUE) on August 2nd, 2019 at $122.19. In approximately 4 months, Bluebird Bio Inc has returned 40.55% as of today's recent price of $72.64....

BLUE : 89.75 (+6.78%)
SmarTrend Watching for Potential Pullback in Shares of Bluebird Bio Inc After 1.18% Gain

Bluebird Bio Inc (NASDAQ:BLUE) traded in a range yesterday that spanned from a low of $74.75 to a high of $77.00. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high...

BLUE : 89.75 (+6.78%)
First Location Signed for Egg Health Hub

via NEWMEDIAWIRE -- Turnkey Capital, Inc. (TKCI) wholly owned subsidiary Egg Health Hub announced that it has signed a Letter of Intent to lease space at The Galleria Mall in Fort Lauderdale, FL.

BLUE : 89.75 (+6.78%)
TKCI : 1.8300 (-8.50%)
Novartis Receives FDA Nod for Adakveo in Sickle Cell Disease

Novartis (NVS) gets FDA nod for Adakveo to reduce the frequency of pain crises in adult and pediatric SCD patients.

NVS : 92.99 (-0.08%)
BMY : 63.82 (-0.19%)
GBT : 76.88 (-0.01%)
BLUE : 89.75 (+6.78%)
bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy

bluebird bio, Inc. (Nasdaq: BLUE) and Forty Seven, Inc. (Nasdaq:FTSV) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven's novel antibody-based...

BLUE : 89.75 (+6.78%)
FTSV : 35.75 (-7.72%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +0.68 , AIZ -0.29 , SBAC +7.43 , SO +0.05 , WELL -0.46
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar